You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

49 search results for: itch

<b>Itch</b>: Neuroimmune Axis in Chronic Pruritic Skin Diseases
expert video

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Dermatology
A review of the neuroimmune axis and the mechanisms involved in perpetuating chronic itch in AD, PN, and CSU.
View more
<b>Itch</b>: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
<b>Itch</b>: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
What Drives Chronic <b>Itch</b> and the <b>Itch</b>-Scratch Cycle in Atopic Dermatitis?
videoanimation

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

Dermatology
Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis
View more
<b>Itch</b>: Neuroimmune Axis in Chronic Pruritic Skin Diseases
expert video

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Dermatology
Dr. Weidinger discusses the intricate neuroinflammatory mechanisms of chronic pruritic skin disease such as AD and PN.
View more
Differences in <b>Itch</b> in AD, PN, and CSU
expert video

Differences in Itch in AD, PN, and CSU

Dermatology
Dr. Shawn Kwatra reviews the distinct characteristics of itch, and the associated patient burden in AD, PN, and CSU.
View more
Exploring Neurosensitization and Pain in Prurigo Nodularis
expert video

Exploring Neurosensitization and Pain in Prurigo Nodularis

Dermatology
Dr. Gil Yosipovitch explains that patients with PN may experience pain due to neurosensitization.
View more
Disease-Specific Aspects of <b>Itch</b> in AD, PN, and CSU
expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

Dermatology
Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.
View more
Unique Characteristics of <b>Itch</b> in AD, PN, and CSU – A Panel Discussion
expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

Dermatology
Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.
View more
Emerging Understanding of Chronic <b>Itch</b>y Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU
expert video

Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU

Dermatology
Review the roles of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.
View more
<b>Itch</b> in AD, PN and CSU: Role of Type 2 Inflammation
expert video

Itch in AD, PN and CSU: Role of Type 2 Inflammation

Dermatology
Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.
View more
The Path to Nodules: Type 2 Inflammation at the Core of Chronic <b>Itch</b> and Fibrosis in Prurigo Nodularis
expert video

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

Type 2 Inflammation
Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FranceChange country/region